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ING5Lysine residues are subject tomany forms of covalentmodiﬁcation andone suchmodiﬁcation is acetylation of the
ε-amino group. Initially identiﬁed on histone proteins in the 1960s, lysine acetylation is now considered as an
important form of post-translational modiﬁcation that rivals phosphorylation. However, only about a dozen of
human lysine acetyltransferases have been identiﬁed. Among them are MOZ (monocytic leukemia zinc ﬁnger
protein; a.k.a. MYST3 and KAT6A) and its paralog MORF (a.k.a. MYST4 and KAT6B). Although there is a distantly
related protein in Drosophila and sea urchin, these two enzymes are vertebrate-speciﬁc. They form tetrameric
complexes with BRPF1 (bromodomain- and PHD ﬁnger-containing protein 1) and two small non-catalytic sub-
units. These two acetyltransferases and BRPF1 play key roles in various developmental processes; for example,
they are important for development of hematopoietic and neural stem cells. The human KAT6A and KAT6B
genes are recurrently mutated in leukemia, non-hematologic malignancies, and multiple developmental disor-
ders displaying intellectual disability and various other abnormalities. In addition, the BRPF1 gene is mutated
in childhood leukemia and adult medulloblastoma. Therefore, these two acetyltransferases and their partner
BRPF1 are important in animal development and human disease.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Since identiﬁcation of the very ﬁrst histone acetyltransferases such
as Hat1 (histone acetyltransferase 1), Gcn5 (general control non-
derepressible 5), PCAF (p300/CBP-associated factor), p300 (adenoviral
E1A-binding protein of 300 kDa) and CBP (CREB-binding protein) in
1996 [1–6], various other proteins with such enzymatic activity have
been described [7–9]. According to sequence similarity, known mam-
malian histone acetyltransferases are organized into threemajor groups
[10–12]. One such group is the GCN5/PCAF family, consisting of GCN5,
PCAF and related proteins [10–12]. The p300/CBP family is another
group that has been extensively characterized [13–15]. Also initially
identiﬁed in 1996 [16,17], the MYST family of proteins forms a third
major group [10,18,19]. The acronym MYST was derived from the four
founding members: human MOZ [17], yeast Ybf2 (renamed Sas3, for
something about silencing 3) [16,20], yeast Sas2 [16] and human
TIP60 (HIV Tat-interacting 60 kDa protein) [21–23]. There are ﬁve
MYST proteins in humans, and the other three members are hMOF
(human males-absent on the first) [24], HBO1 (HAT bound to ORC1)
[25] and MORF [26]. Members of this family only share the MYSTdomain [10]. Compared to the GCN5/PCAF and p300/CBP groups, this
family is more diverse in domain organization, complex formation,
and biological function [10,18,19]. In the past two decades, these pro-
teins have been systematically renamed twice. In the ﬁrst nomenclature
system,MYST1, MYST2, MYST3 andMYST4were given to HBO1, hMOF,
MOZ and MORF, respectively; incidentally, TIP60 was omitted in this
system. The second nomenclature system is part of the ‘lysine (K) ace-
tyltransferase (KAT)’ proposal adopted in 2007 [11]. According to this,
TIP60, MOZ, MORF, HBO1 and hMOF were renamed KAT5, KAT6A,
KAT6B, KAT7 and KAT8, respectively. It should be noted that mouse
Morf was also identiﬁed as Querkopf (‘squarhead’ in German) after
the head shape ofmutantmice deﬁcient inMorf [27].While the KAT no-
menclature system is gradually being adopted in the literature, tradi-
tional names such as MOZ, MORF, HBO1, hMOF and TIP60 are still
being widely used. Hereafter we will use acronyms in both systems
mainly according to how the names are cited in original publications.
2. MOZ and MORF as transcriptional coactivators with intrinsic
enzymatic activity
These two acetyltransferases have similar domain organizations
(Fig. 1A) [10,28]. In the yeast, there are three MYSTmembers, Esa1 (es-
sential Sas2-related acetyltransferase 1), Sas2 and Sas3 [29]. Gcn5, Hat1,
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Fig. 1.Domain organization ofMOZ/MORF and their disease-caudingmutations. (A) BothMOZ andMORF are composedof tandemPHD ﬁngers, aMYSTdomain, an acidic region and a Ser/
Met (SM)-rich domain. In addition to the PHDﬁngers andMYST domain, the regionN-terminal to the PHDﬁnger is also conserved inDrosophila Enok, so this region has been referred to as
the NEMM (N-terminal part of Enok, MOZ andMORF) domain [28]. This domain shows some sequence similarity to histones H1 and H5, thus also known as the H15 domain [28]. (B) The
MOZ andMORF genes are recurrently mutated in leukemia, non-hematologic malignancies, and developmental disorders with the common characteristics of intellectual disability and
developmental delay. Vertical arrows pointing to locations of disease-causing chromosomal translocations and point mutations affecting MOZ (brown) and MORF (blue). For leuke-
mia-associated translocations, the corresponding fusion partners are also indicated. Except the two translocations at the very N-terminal region, many other mutations remove the SM
domain but leave the veryN-terminal region and theMYST domain intact. KAT6A (a.k.a. MOZ) syndrome refers to a new syndrome characteristic ofmicrocephaly and global developmen-
tal delay, whereas KAT6B (a.k.a. MORF) syndrome includes genitopatellar syndrome and related developmental disorders. For simplicity, only a few arrows are used to illustrate mutation
positions related to KAT6A/B syndromes; refer to several published reports for complete list ofmutations [78,79,130,134]. Abbreviations: CBP, CREB-binding protein; p300, E1A-associated
p300 kDa protein (paralogous to CBP); TIF2, transcription intermediary factor 2 (known to bind p300 and CBP).
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and Eco1 (establishment of cohesion 1) are the other ﬁve lysine acetyl-
transferases known in yeast [11,29,30], so theMYST family is important
for controlling yeast histone acetylation. There are about a dozen lysine
acetyltransferases in mammals [10,11] and the mammalian MYST fam-
ily contains ﬁve members, so this family is critical for maintaining his-
tone acetylation and lysine acetylome in general [30]. The deﬁning
feature for members of this family is the MYST domain (Fig. 1A),
which confers intrinsic acetyltransferase activity [10,28]. This domain
shares an acetyl-CoA binding motif with GCN5, but displays no similar-
ity to p300 and CBP [10,11]. In addition to the MYST domain, the N-
terminal part of MOZ or MORF is highly similar to Drosophila Enok
(named after ‘enoki mushroom bodies’ in mutant ﬂies lacking this pro-
tein), which is crucial for neuroblast proliferation [31] and oocyte devel-
opment in the female germline [32,33]. This N-terminal part contains
the very N-terminal region, tandem PHD ﬁngers and the MYST domain
(Fig. 1A) [28].
As shown with other members of this family, the MYST domains of
MOZ and MORF confer intrinsic acetyltransferase activities [26,27,34,
35]. While MOZ and MORF acetylate histone H3 at Lys-9 and -14 [36,
37], Enok speciﬁcally targets Lys-23 [33]. The tandem PHD ﬁngers of
human KAT6A are important for histone H3 binding (Fig. 1A) [38–40].
Arg-2 or Lys-4 methylation inhibits, but Lys-14 acetylation promotes,
this binding, thereby providing a mechanism for crosstalk between
modiﬁcations at different sites [38–40]. This also serves as a potentially
important mechanism to survey the gene locus-speciﬁc modiﬁcation
status and control its acetylation by the MYST domain [40].
C-terminal to theMYST domain ofMOZ orMORF are an acidic region
and a serine/methionine (SM)-rich domain (Fig. 1A). Both are present
in two zebraﬁsh orthologs but not in Drosophila Enok or a related sea
urchin protein [28], indicating that MOZ and MORF are vertebrate-
speciﬁc. While little is known about the function of the acidic region,
the SM domain possesses potent transcriptional activation potential
(Fig. 1A) [26,28,34]. MOZ and MORF do not bind DNA directly, so they
function as coactivators for DNA-binding transcription factors [28]. Con-
sistent with this, MOZ and MORF interact with RUNX transcription
factors (Fig. 2A) [35,41,42], and MOZ also acetylates p53 to activate
p21 transcription (Fig. 2B) [43]. Thus,MOZ andMORF are transcription-
al coactivators with intrinsic acetyltransferase activity.3. MOZ and MORF form tetrameric complexes with BRPF1 and two
other subunits
In 2006, puriﬁcation of ING5 (inhibitor of growth 5) from HeLa cell
extracts identiﬁed a tetrameric complex containing BRPF1, MOZ and
EAF6 (homolog of yeast Esa1-associated factor 6) (Fig. 3A & C) [44]. In
the complex, MOZ can be replaced with MORF [44]. Recent puriﬁcation
of BRPF1 fromHeLa cell extracts revealed that it also forms a tetrameric
complex with HBO1, ING4/5 and EAF6 (Fig. 3B & D) [45,46].
BRPF1 was formerly known as BR140 (bromodomain protein of
140 kDa), incidentally cloned in 1994 as a zinc ﬁnger protein containing
a bromodomain similar to two such domains on the 250-kDa subunit of
the transcription initiation factor TFIID [47]. Subsequent cloning of
two leukemia-associated fusion partners on chromosomes 10 and 17
unraveled a Cys/His-rich domain that the fusion partners share with
BR140 [48–50]. This domain harbors two PHD (plant homeodomain-
linked) ﬁngers joined by a C2HC zinc knuckle and is thus named the
PZP (PHD-zinc knuckle-PHD)module (Fig. 4A) [51]. In BRPF1, thismod-
ule is located in the middle part but N-terminal to the bromodomain
(Fig. 4A). In light of this PZP module and the bromodomain, new pro-
teins similar to BRPF1 were sought after, leading to the identiﬁcation of
BRL (BR140-like protein), now known as BRPF2 or BRD1 (bromodomain
protein 1) (Fig. 4B) [52]. BRPF3 is a third paralog (Fig. 4B), whichwas un-
covered during genome annotation. These three proteins form a small
but unique family of multidomain chromatin regulators (Fig. 4A–B)
[28,53,54].
The PZP module is also present in other chromatin modiﬁers such as
the leukemia-associated methyltransferase NSD1 and the demethylase
GASC1 [51], further supporting a role in chromatin regulation. Moreover,
this module is found in three JADE [protein encoded by gene (J) for apo-
ptosis and differentiation in epithelia] proteins (Fig. 4C) [44,55]. Flanking
the PZPmodule of BRPF1 are two smallmotifs similar to EPC (enhancer of
polycomb) proteins (Fig. 4A & D) [44,51,56]. The N-terminal motif con-
tributes to interaction with MOZ and MORF, while the C-terminal motif
binds to ING5 and EAF6 (Fig. 3C) [36,44], indicating that BRPF1 serves
as a scaffold for complex formation (Fig. 3A) [36]. The bromodomain of
BRPF1 has acetyllysine-binding ability [57], whereas the PZP modules of
BRPF1 and BRPF2 recognize the unmodiﬁed N-terminus of histone H3
[46,58] and the second PHD ﬁnger of BRPF2 is also known to bind directly
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Fig. 2.Models showing howBRPF1 is targeted to chromatin for speciﬁc transcriptional reg-
ulation. (A) RUNX transcription factors bind to DNA and recruit theMOZ orMORF histone
acetyltransferase, along with the trimeric complex composed of BRPF1, ING5 and EAF6. It
is unclear whether MOZ/MORF, BRPF1 and ING5 also utilize their histone-binding do-
mains to interact with chromatin [132]. (B) The tumor suppressor p53 binds to DNA
and recruits the MOZ/MORF histone acetyltransferases, which in turn form tetrameric
complexes with BRPF1, ING5 and EAF6. As in (A), it remains unclear whether MOZ/
MORF, BRPF1 and ING5 also utilize their histone-binding domains to recognize chromatin.
(C–D) BRPF1 forms a trimeric complex with ING5 and EAF6 to recruit the histone acetyl-
transferaseMOZ,MORF (C) orHBO1 (D) to regulate gene expression. Dark questionmarks
denote unknown consequences of recruitment of Moz/Morf and Hbo1. Ac, acetylation.
(E) It remains possible that BRPF1 also acts through an unknown partner(s) as indicated
by a yellow oval along with a red question mark.
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N-terminus of histone H3 in a manner sensitive to modiﬁcations at Lys-
4 [46,58], thereby indirectly ‘reading’ histone modiﬁcations. Located at
the C-terminal part of BRPF1 is a highly conserved PWWP domain
(Fig. 4A), which forms a speciﬁc pocket for lysine-methylated histone
H3 [60,61].
Interestingly, despite their high sequence similarity to BRPF1, both
BRPF2 and BRPF3 (Fig. 4A) preferentially form complexes with HBO1,
rather than with MOZ and MORF (Kezhi Yan & X.J.Y., unpublished
data) [45,46]. Thus, even at the molecular level, BRPF1 can function
quite differently from BRPF2 and BRPF3. Strikingly, BRPF1 association
switches the substrate speciﬁcity of HBO1 from nucleosomal histone
H4 to H3 [46], indicating a dominant role of BRPF1 in controlling the
substrate speciﬁcity [46,62]. Notably, BRPF1 does not interact with
other acetyltransferases such as hMOF [63] and p300 [45], supporting
that association with MOZ, MORF and HBO1 is speciﬁc (Fig. 2A–B).
Thus, BRPF1 speciﬁcally interactswith three different acetyltransferases
to govern their enzymatic properties.4. MOZ and MORF in vertebrate development
Inactivation of the mouse Moz gene leads to embryonic lethality
around embryonic (E) day 14.5 [64]. Mutant embryos at E14.5 are blood-
less and have small liver, indicating defective hematopoiesis. Analyses of
two different knockout strains lead to the conclusion thatMoz is required
for maintaining fetal hematopoietic stem cells [64,65]. In addition, a
knock-in mutant mouse strain has been engineered [66] to express the
point mutant G657E, known to be defective in histone acetylation [67].
Compared to wild-type littermates, the resulting homozygotes display
shortened lifespan, low body weight, small thymus and spleen, and pro-
liferation defects in various hematopoietic progenitors [66], supporting
the importance of the acetyltransferase activity of Moz in vivo. Moreover,
themouseMoz gene is required for normal B cell development, as well as
for optimal lymphoma development induced byMyc [68,69]. In addition,
loss of Moz leads to senescence of mouse embryonic ﬁbroblasts and neu-
ral stem cells [70,71]. The requirement for lymphoma development and
cell proliferation suggests that Moz has an oncogenic role.
The biological function ofmouseMorf has been investigated in a gene-
trap strain possessing ~10% residual mRNA [27]. Heterozygous mutant
animals are normal, but the homozygotes die at weaning (i.e., ~3 weeks
of age) and display dwarﬁsm, craniofacial abnormalities and cerebral de-
fects [27]. Related to the cerebral defects, Morf is important for regulating
neural stem cells [72,73]. These ﬁndings shed some light on defects char-
acteristic of developmental disorders due to mutations in theMOZ and
MORF genes [74–79]. The phenotypes observed with these mutant mice
indicate that although they are interchangeable in various molecular
and cell-based studies in vitro [26,34,36], MOZ and MORF have quite dis-
tinct functions in vivo.
While MOZ and MORF are large (~240 kDa, Fig. 3C), HBO1 is much
smaller (Fig. 3D). Its N-terminal domain is different from those of
MOZ and MORF (Fig. 3A & D). No direct links to diseases have been un-
covered yet for human HBO1, but mouse Hbo1 is essential for embryo
development [80]. Inactivation of the mouse gene leads to embryonic
lethality at E10.5 [80]. Importantly, it is a major acetyltransferase for
Lys-14 acetylation of histone H3 in mouse embryonic ﬁbroblasts [80]
and other cells [45,81]. This is slightly different in budding and ﬁssion
yeast, where both Sas3 (similar to HBO1) and Gcn5 contribute to his-
tone H3 acetylation at Lys-14 [82,83]. This histone mark (H3K14ac) is
important. For example, it controls cell cycle progression [82,83], factor
recruitment to chromatin [38], H3K4me3 demethylation [84] and RNAi-
mediated gene silencing [85]. Studies using human cells indicate a key
role of HBO1 in DNA replication [86,87], but the mouse gene is not re-
quired [80]. Whether this discrepancy is due to species difference
awaits further investigation.5. MOZ and MORF in leukemia, solid tumors and
developmental disorders
In 1996, theMOZ gene was ﬁrst identiﬁed as a fusion partner in the
recurrent chromosome translocation t(8;16)(p11;p13) associated with
acute myeloid leukemia (Fig. 1B) [17]. This gene is fused to that of CBP,
producing an aberrant transcript encoding the fusion protein MOZ-CBP
[10,17]. Similarly, in the leukemia-associated chromosome transloca-
tion t(8;22)(p11;q13), theMOZ gene is fused to that of p300, producing
the fusion protein MOZ-p300 [88]. TheMOZ gene is also rearranged in
hematologic malignancies with the inversion inv(8)(p11q13), generat-
ing fusion proteins with TIF2 (transcription intermediary factor 2, a
known partner of p300/CBP) (Fig. 1B) [89,90]. The resulting MOZ-TIF2
fusion proteins promote self-renewal of leukemic stem cells [67,91,
92]. In addition, theMOZ gene is fused to a novel partner, LEUTX (leucine
twenty homeobox), in therapy-related acute myeloid leukemia with
t(8;19)(p11;q13) [93]. Reminiscent of the MOZ gene, the MORF gene
is fused to the CBP gene in translocation t(10;16)(q22;p13) associated
with acute myeloid leukemia (Fig. 1B) [94,95].
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Fig. 3. Architecture of BRPF1 complexes and links of MOZ/MORF to cancer and other diseases. (A) Cartoon showing a tetrameric complex composed of MOZ (or MORF), BRPF1, ING5 and
EAF6. BRPF1 serves as a scaffold, to promote complex formation and stimulate acetylation of nucleosomal histone H3. In the complex, ING5 can be replaced with ING4. (B) Same as
(A) except that the catalytic subunit is HBO1 instead of MOZ or MORF. (C) Molecular architecture showing how different domains are involved in tetrameric complex formation. MOZ
and MORF are two paralogs, each comprising multiple domains: tandem PHD ﬁngers, a MYST domain, and a transcriptional activation domain. It is striking that only a small region of
MOZ and MORF (red vertical arrow) is required for interaction with BRPF1. EPC-II of BRPF1 serves as the binding surface for ING5 and EAF6. BRPF1 forms a trimeric core with ING5
and EAF6 for interaction with MOZ and MORF. (D) Molecular architecture illustrating how different domains are involved in tetrameric HBO1 complex formation. HBO1 is much smaller
thanMOZ orMORF, and does not have the PHD ﬁngers and SMdomain ofMOZ orMORF. However, it possesses an uncharacterized zincﬁnger (ZF) and a serine-rich domain (not depicted
here). It is unclear whether the C-terminal region of the MYST domain mediates HBO1 interaction with BRPF1 as shown for MOZ and MORF (C).
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are altered in solid tumors. The MOZ gene is mutated in esophageal
adenocarcinoma [96] and abnormal expression of mouse Moz contrib-
utes to metastasis of medulloblastoma [97]. The MORF gene is altered
in leiomyomata [98,99], breast cancer [100] and castration-resistant
prostate cancer [101]. In leiomyomatawith the chromosomal transloca-
tion t(10;17)(q22;q21), theMORF gene is fused to the gene of KANSL1
(KAT8 regulatory NSL complex subunit 1), leading to expression of a
fusion protein containing the NEMM domain of MORF (Fig. 1A) and a
KANSL1 domain able to interact with KAT8 [99]. This suggests that
mistargeted acetylation is oncogenic, which is reminiscent of fusion of
MOZ and MORF to p300, CBP and TIF2 in leukemia (Fig. 2B). Moreover,
theMOZ andMORF genes have both been identiﬁed as top-ranking tar-
gets ampliﬁed in different types of cancer [102]. Mouse studies indicate
that Moz is required for lymphoma development induced by Myc [68]
and its loss leads to senescence of mouse embryonic ﬁbroblasts and
neural stem cells [70,71]. All of these support thatMOZ has an oncogen-
ic role.
In addition to cancer, the MORF gene is mutated in four different
developmental disorders (Fig. 1B): Noonan syndrome-like disorder
[103], Ohdo syndrome [74,104], genitopatellar syndrome [75,76] and
blepharophimosis–ptosis–epicanthus inversus syndrome [77]. A boy
with the Noonan syndrome-like disorder displays reduced growth,
cardiac defects, distinctive facial dysmorphism, and variable cognitivedeﬁcits [103]. Patients with Ohdo syndrome exhibit eyelid dysplasia,
mask-like facial appearance and severe intellectual disability [74].
Genitopatellar syndrome is associated with patellar aplasia or hypopla-
sia, external genital abnormalities and severe intellectual disability [75,
76]. Blepharophimosis–ptosis–epicanthus inversus syndrome is charac-
terized with abnormal eyelid development and distinct facial features,
and some female patients also exhibit ovarian insufﬁciency [77]. Di-
verse defects in patients of these four genetic diseases support that
MORF functions as a pleiotropic regulator in various biological process-
es [26]. Importantly, two recent studies have also identiﬁed recurrent
MOZ gene mutations in previously unrecognized syndromes that dis-
play intellectual disability and global developmental delay (Fig. 1B)
[78,79].
A key issue is what molecular mechanisms underlie cancer and
developmental disorders caused by mutations in the MOZ and MORF
genes. These developmental disorders share the common characteris-
tics of intellectual disability and craniofacial abnormalities. Related to
this, Morf-deﬁcient mice show defects in cerebral and bone develop-
ment [27]. Morf is required for adult neurogenesis [72,73] and Moz is
also important for NSCs [71]. In addition, Moz regulates neural crest
development and craniofacial morphogenesis [105]. Moreover, both
ﬁsh and mouse Moz proteins modulate skeletal development [37,
106–108]. The pleiotropic effects of the human MOZ and MORF gene
mutations are also consistent with the molecular studies that both
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1822 X.-J. Yang / Biochimica et Biophysica Acta 1853 (2015) 1818–1826MOZ and MORF function as transcriptional coactivators for RUNX tran-
scription factors, the p53 tumor suppressor and perhaps others
(Fig. 2A–B).
6. BRPF1 and its paralogs in animal development and human disease
BRPF1 is conserved from Caenorhabditis elegans to humans [28]. In
budding and ﬁssion yeast, there is one related protein (Nto1, for NuA
three ORF 1), but it is an ortholog of JADEs [62,83,109,110]. Although
the biological function of Drosophila Brpf1 remains unclear, the
C. elegans ortholog Lin-49 is known to regulate neuron asymmetry,
hindgut development and reproduction [111–113]. Lin-49 genetically
interacts with two proteins distantly related toMOZ and EAF6 [113]. In-
activation of zebraﬁsh Brpf1 affects anteriorHox gene expression and al-
ters pharyngeal segmental identity [114]. Such a phenotype is
reminiscent of what was reported for inactivation of zebraﬁsh Moz
[106]. Moreover, inactivation ofmedaka Brpf1 reduces expression of an-
terior and posterior Hox genes, thereby altering craniofacial and caudal
skeletons, respectively [115]. Therefore, ﬁsh Brpf1 interacts withMoz to
regulate Hox gene expression. While there is only one ortholog in
C. elegans or Drosophila, Brpf1 has two paralogs (Brpf2 and Brpf3) in
ﬁsh and other vertebrates (Fig. 4A–B). Functions of ﬁsh Brpf2 and
Brpf3 remain to be determined.
We have characterized amouse strain containing two LoxP sites and
a LacZ reporter cassette inserted at the mouse Brpf1 locus [116]. Using
the LacZ reporter, we determined the expression atlas and the results
suggest an important role of mouse Brpf1 in different developmental
processes [116]. Total knockout embryos die at E9.5, indicating an es-
sential role in embryogenesis [116,117]. Because of high expression in
the brain [116], we have recently generated forebrain-speciﬁc knock-
outs and discovered that Brpf1 is key to development of the cerebral
cortex and hippocampus [63,118]. Notably, Brpf1 is crucial for dentate
gyrus development by regulating neural stem cells [63,118]. To under-
stand the underlying mechanisms, we have utilized microarray-based
gene expression analysis to investigate how Brpf1 loss alters thetranscriptome, discovering that mouse Brpf1 regulates expression of
Hox and multiple other genes in the mouse forebrain [63,118].
Phenotypes of Brpf1−/− embryos are much more severe than those
ofMoz−/− embryos andMorf-deﬁcient mice [27,64,65]. It may be relat-
ed to the ability of Brpf1 to regulate bothMoz andMorf (Fig. 2C) [36,44].
Alternatively, Brpf1 has functions independent of them. Of relevance,
Brpf1 also interacts with Hbo1 (Fig. 2D) [45,46]. Also, it is still possible
that Brpf1 acts independently of Moz, Morf and Hbo1 in vivo; if so,
Brpf1 may interact with an unidentiﬁed factor(s) (Fig. 2E). Inactivation
of mouse Brpf2 leads to embryonic lethality at E15.5, with neural tube
defects, abnormal eye development and faulty erythropoiesis [45]. In
contrast, mouse Brpf3 is non-essential (Kezhi Yan & X.J.Y., unpublished
data). Thus, despite their sequence similarity (Fig. 4A–B), mouse
Brpf1, Brpf2 and Brpf3 have quite distinct roles in vivo.
As illustrated in Fig. 5A, the human BRPF1 gene is recurrently mutat-
ed in childhood leukemia [119] and adult medulloblastoma [120]. The
mutations appear to diminish the function of BRPF1, suggesting that it
plays a tumor-suppressor role. Both BRPF2 and BRPF3 are also altered
in cancer (Fig. 5A–B) [119–121]. One leukemia-associated chromosom-
al translocation leads to expression of a fusion protein containing a DNA
binding domain of the PAX5 transcription factor and entire BRPF2, sug-
gesting that mistargeted BRPF2 is oncogenic. ING5 is a part of the ING
(inhibitor of growth) family, whose founding members were initially
identiﬁed as inhibitors of cell growth [122]. The EAF6 gene is rearranged
in endometrial stromal sarcoma [123,124]. Thus, like MOZ and MORF,
the BRPF1–ING5–EAF6 subcomplex plays a direct role in cancer. The
crucial role of mouse Brpf1 in development [63,116–118], as well as
its close partnership with MOZ and MORF (Fig. 2A) [36,44,46], suggests
that human BRPF1 may also be important in different developmental
disorders.
7. Conclusions and future directions
It is now widely recognized that both genetic and epigenetic mech-
anisms are critical in human development and disease [125,126].
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Fig. 5.The BRPF1 gene is recurrentlymutated in childhood leukemia and adultmedulloblastoma. (A) Illustrated aremutations that have been discovered in the BRPF1 and BRPF3 genes. The
mutations present in adult medulloblastoma are indicated with dark letters, whereas those found in pediatric leukemia are shown in blue. fs, reading frame shift; *, translational termi-
nation. The mutations are composed from data published in two recent studies [119,120]. Neither study has uncovered any point mutations on the BRPF2 gene. (B) Comparison of BRPF2
with a leukemia-associated fusion protein containing a part of the transcription factor PAX5. In childhood acute lymphoblastic leukemia, the paired domain (PD) of PAX5 is fused to entire
BRPF2. This paired domain confers speciﬁc DNA binding and is thus able to recognize certain enhancers, so discovery of this fusion protein in leukemia suggests that mistargeted BRPF2
may lead to leukemogenesis.
1823X.-J. Yang / Biochimica et Biophysica Acta 1853 (2015) 1818–1826Related to the epigenetic angle, hundreds of chromatin regulators have
been identiﬁed and characterized at the molecular level [11,127–129],
so an important research direction is to pinpoint pathophysiological
roles of different chromatin regulators. In this regard, the MOZ and
MORF genes are recurrently mutated in cancer [28,96,97,101,102] and
multiple developmental disorders [74–79,103,130]. In addition, both
MOZ and MORF interact with—and their acetyltransferase activities
are stimulated by—the multivalent chromatin regulator BRPF1 [28,36,
44]. Mouse Brpf1 is important for regulating different developmental
processes [63,116–118], and the human BRPF1 gene is mutated in pedi-
atric lymphoma and adult meduloblastoma [119,120]. Related to the bi-
ological functions, mouse Brpf1 regulates different developmental
processes, including mouse embryo survival [116,117] and forebrain
development [63,118], suggesting the intriguing possibility that the
human BRPF1 gene is also mutated in developmental disorders. There-
fore, since the initial identiﬁcation in 1996 and 1999 [17,26], MOZ and
MORF have emerged as two unique chromatin regulators with impor-
tant roles in animal development and human diseases.
As for future directions, how to correlate information from molecu-
lar studies in cell-free and cell-based systems, and ﬁsh and mouse ge-
netic analyses, with symptoms in human diseases with mutations in
theMOZ,MORF and BRPF1 genes remains an important question deserv-
ing continued research attention. While good progress has been made
about the molecular and biological functions of these proteins, how
their functions are regulated, e.g., by cellular signaling networks, re-
mains a question that little is known about. How different histone-
binding domains of MOZ/MORF–BRPF1 complexes (Fig. 3A & C) cooper-
ate with each other, as well as with other epigenetic regulators, to
confer genome-wide actions is another important question awaiting
further investigation. In addition to histones, numerous non-histone
proteins have been identiﬁed [131]. For example, ~5% bacterial and
mammalian proteins are acetylated on lysine residues [30]. In contrast
to numerous protein kinases maintaining the human kinome, only
over a dozen lysine acetyltransferases have been identiﬁed. In this con-
text, an important question iswhetherMOZandMORF acetylate various
non-histone proteins. The last important question is how to translate
the knowledge that we have acquired andwill acquire to the clinics. Re-
lated to this, different domains of MOZ, MORF and BRPF1 are potential
drug targets (Figs. 1 & 4) [132]. In this regard, a highly-speciﬁc com-
pound targeting the bromodomain of BRPF1 has been developed
[133]. Overall, through dedicated efforts frommultiple research labora-
tories with complementary expertise, we have learned a lot aboutMOZ,MORF and their binding partners. However, there are still a lot of very
important questions awaiting even more concerted research attention.
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